Profusa, Inc. (NASDAQ:PFSA) stock rallied on Friday as the company is launching its Healthcare Research version of the Lumee tissue oxygen monitoring system.The stock is trading with a massive volume of 140.93 million versus the average volume of 25.7 million, according to Benzinga Pro data.The company announced that its Lumee tissue oxygen products are now commercially available for contract research organizations (CROs), targeting a market projected to grow from approximately $47.9 billion in 2025 to over ...

Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR BERKELEY, Calif, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the launch of its Healthcare Researc ...